| Trial ID: | L3319 |
| Source ID: | NCT00832624
|
| Associated Drug: |
Sitagliptin
|
| Title: |
The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00832624/results
|
| Conditions: |
Diabetes Mellitus Non-insulin-dependent
|
| Interventions: |
DRUG: sitagliptin
|
| Outcome Measures: |
Primary: Change From Baseline in HbA1c (Hemoglobin A1c) at Week 18, Glycosylated hemoglobin (HbA1c) was to be measured as the percentage of hemoglobin that has glucose bound to it; however, the study was terminated early therefore no laboratory tests were performed, and no outcome data was collected., Baseline and Week 18 |
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
10
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2008-11-26
|
| Completion Date: |
2009-09-02
|
| Results First Posted: |
2010-10-11
|
| Last Update Posted: |
2017-05-23
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00832624
|
